Compugen (CGEN) COO discloses 400,000 share options in Form 3

Rhea-AI Filing Summary

Compugen Ltd.’s Chief Operating Officer Pierre Ferre has filed a Form 3 reporting his existing holdings of share options. The filing lists options over a total of 400,000 Ordinary Shares, with exercise prices ranging from 3.0000 to 6.4500 and expiration dates between 2031 and 2035.

One option grant is already fully vested, while others vested or vest 25% on dates in 2023, 2024 and 2025, with the remaining portions vesting in 12 equal quarterly installments, subject to his continued service. A further grant begins vesting 25% on September 30, 2026, then continues in 12 quarterly installments.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Ferre Pierre

Role Chief Operating Officer

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 100,000 shares (Direct)

Footnotes (1)

1. Fully vested. This option vested 25% on March 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on September 30, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ferre Pierre

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

3a. Foreign Trading Symbol
[CGEN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(1)	07/27/2031	Ordinary Shares	100,000	$6.45	D
Share Option (right to buy)	(2)	03/24/2032	Ordinary Shares	65,000	$5	D
Share Option (right to buy)	(3)	11/09/2032	Ordinary Shares	30,000	$3	D
Share Option (right to buy)	(4)	08/03/2033	Ordinary Shares	65,000	$3	D
Share Option (right to buy)	(5)	07/31/2034	Ordinary Shares	70,000	$4	D
Share Option (right to buy)	(6)	08/05/2035	Ordinary Shares	70,000	$4	D

Explanation of Responses:

1. Fully vested.

2. This option vested 25% on March 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

3. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

4. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

5. This option vested 25% on September 30, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

6. This option vests 25% on September 30, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Pierre Ferre	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Compugen (CGEN) Form 3 for Pierre Ferre report?

The Compugen Form 3 reports Chief Operating Officer Pierre Ferre’s existing holdings of share options. It lists multiple option grants over 400,000 Ordinary Shares, detailing their exercise prices, expiration dates, and vesting schedules tied to his continued service with the company.

How many Compugen (CGEN) shares are covered by Pierre Ferre’s options?

Pierre Ferre’s reported options cover 400,000 underlying Ordinary Shares. These are split across six separate “Share Option (right to buy)” grants, each with its own exercise price, expiration date, and vesting timetable as disclosed in the Form 3 derivative holdings table.

What are the exercise prices of Pierre Ferre’s Compugen (CGEN) options?

The Form 3 shows exercise prices of 6.4500, 5.0000, 3.0000 and 4.0000 per share. Each price applies to a different option grant, reflecting distinct award terms and timelines for potential exercise into Compugen Ordinary Shares if conditions are met.

When do Pierre Ferre’s Compugen (CGEN) options expire?

The reported options expire on dates ranging from July 27, 2031 through August 5, 2035. Each option grant has a specific expiration date, giving multi‑year windows during which Ferre may exercise the rights, subject to vesting and continued service conditions.

How do Pierre Ferre’s Compugen (CGEN) options vest over time?

One option is fully vested, while others vest 25% on specific dates in 2023, 2024 and 2025, with remaining portions vesting in 12 equal quarterly installments. Another grant vests 25% on September 30, 2026, then continues vesting in 12 quarterly installments, contingent on continued service.

Is the Compugen (CGEN) Form 3 a buy or sell transaction for Pierre Ferre?

The Form 3 does not report new buys or sells; it discloses existing derivative holdings. The entries are classified as holdings of “Share Option (right to buy)” awards, showing remaining option positions and vesting terms rather than open‑market purchases or sales of Compugen shares.